Variations of CYP3A activity induced by antiretroviral treatment in HIV

Jan 19, 2005 - phenotyping test during the first day(s) of drug admin- istration was motivated, in part, by our intention to determine whether a possible ...
270KB taille 28 téléchargements 249 vues
Eur J Clin Pharmacol (2005) 60: 865–873 DOI 10.1007/s00228-004-0855-8

PHARMACOKINETICS AND DISPOSITION

Jacques Fellay Æ Catia Marzolini Æ Laurent Decosterd Kerry Powell Golay Æ Pierre Baumann Æ Thierry Buclin Amalio Telenti Æ Chin B. Eap

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients Received: 30 April 2004 / Accepted: 8 October 2004 / Published online: 19 January 2005 Ó Springer-Verlag 2005

Abstract Objective: To measure the in vivo variations of CYP3A activity induced by anti-HIV drugs in human immunodeficiency virus (HIV)1-positive patients. Methods: A low oral dose of midazolam (MID) (0.075 mg) was given to the patients and the 30-min total 1-OH midazolam (1-OHMID)/MID ratio was determined. Patients were phenotyped either before the introduction of antiretroviral treatments (control group, 90 patients) or after a variable period of antiretroviral treatment (56 patients). Twenty-one subjects underwent multiple phenotyping tests (before and during the course of the treatment). Results: The median MID ratio was 3.51 in the control group (range 0.20–14.6). It was 5-fold higher in the group with efavirenz (28 patients; median, range: 16.0, 3.81– 367; P